Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients
Jernström, Helena LU ; Frenander, J ; Fernö, Mårten LU and Olsson, Håkan LU
(1999)
In British Journal of Cancer
80(9).
p.1453-1458
- Abstract
- Nine hundred and eighty-four breast cancer patients were interviewed regarding exogenous hormonal use. This represents a random sample of breast cancer patients in Southern Sweden referred to the Department of Oncology at Lund for treatment between 1978 and 1997 (excluding 1980 and 1981) with a 100% follow-up. Ever-use of hormone replacement therapy (HRT) prior to diagnosis was significantly associated with a longer overall survival in women with their breast cancer diagnosed at ages 45 and above, relative risk (RR) of dying 0.73 (95% confidence interval (CI) 0.62-0.87; P = 0.0005). Ever use of HRT prior to breast cancer diagnosis was significantly positively associated with overall longer survival after adjustment for T-stage, N-stage,... (More)
- Nine hundred and eighty-four breast cancer patients were interviewed regarding exogenous hormonal use. This represents a random sample of breast cancer patients in Southern Sweden referred to the Department of Oncology at Lund for treatment between 1978 and 1997 (excluding 1980 and 1981) with a 100% follow-up. Ever-use of hormone replacement therapy (HRT) prior to diagnosis was significantly associated with a longer overall survival in women with their breast cancer diagnosed at ages 45 and above, relative risk (RR) of dying 0.73 (95% confidence interval (CI) 0.62-0.87; P = 0.0005). Ever use of HRT prior to breast cancer diagnosis was significantly positively associated with overall longer survival after adjustment for T-stage, N-stage, M-stage, year of diagnosis and age at diagnosis, RR of dying 0.78 (95% CI 0.65-0.93; P = 0.006). Hormone replacement therapy use and oestrogen receptor positivity were independently significantly associated with overall longer survival, P = 0.005 and P < 0.0001, respectively, in one model. HRT use and progesterone receptor positivity were also independently significantly associated with longer overall survival, P = 0.003 and P = 0.0003, respectively, in another model. The mode of diagnosis was known in 705 women. Mammography screening was not more common among HRT users compared with never-users, where this information was available. Both mammography screening and HRT use were independently associated with longer survival, P = 0.002 and P = 0.038 respectively. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1114310
- author
- Jernström, Helena
LU
; Frenander, J
; Fernö, Mårten
LU
and Olsson, Håkan
LU
- organization
- publishing date
- 1999
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- breast cancer, overall survival, HRT, oestrogen receptor, progesterone receptor
- in
- British Journal of Cancer
- volume
- 80
- issue
- 9
- pages
- 1453 - 1458
- publisher
- Nature Publishing Group
- external identifiers
-
- pmid:10424750
- scopus:0032989896
- pmid:10424750
- ISSN
- 1532-1827
- DOI
- 10.1038/sj.bjc.6690543
- language
- English
- LU publication?
- yes
- id
- 54fd38c6-e386-4c97-b552-544a3f3cb835 (old id 1114310)
- date added to LUP
- 2016-04-01 12:37:57
- date last changed
- 2022-01-27 07:44:55
@article{54fd38c6-e386-4c97-b552-544a3f3cb835,
abstract = {{Nine hundred and eighty-four breast cancer patients were interviewed regarding exogenous hormonal use. This represents a random sample of breast cancer patients in Southern Sweden referred to the Department of Oncology at Lund for treatment between 1978 and 1997 (excluding 1980 and 1981) with a 100% follow-up. Ever-use of hormone replacement therapy (HRT) prior to diagnosis was significantly associated with a longer overall survival in women with their breast cancer diagnosed at ages 45 and above, relative risk (RR) of dying 0.73 (95% confidence interval (CI) 0.62-0.87; P = 0.0005). Ever use of HRT prior to breast cancer diagnosis was significantly positively associated with overall longer survival after adjustment for T-stage, N-stage, M-stage, year of diagnosis and age at diagnosis, RR of dying 0.78 (95% CI 0.65-0.93; P = 0.006). Hormone replacement therapy use and oestrogen receptor positivity were independently significantly associated with overall longer survival, P = 0.005 and P < 0.0001, respectively, in one model. HRT use and progesterone receptor positivity were also independently significantly associated with longer overall survival, P = 0.003 and P = 0.0003, respectively, in another model. The mode of diagnosis was known in 705 women. Mammography screening was not more common among HRT users compared with never-users, where this information was available. Both mammography screening and HRT use were independently associated with longer survival, P = 0.002 and P = 0.038 respectively.}},
author = {{Jernström, Helena and Frenander, J and Fernö, Mårten and Olsson, Håkan}},
issn = {{1532-1827}},
keywords = {{breast cancer; overall survival; HRT; oestrogen receptor; progesterone receptor}},
language = {{eng}},
number = {{9}},
pages = {{1453--1458}},
publisher = {{Nature Publishing Group}},
series = {{British Journal of Cancer}},
title = {{Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients}},
url = {{http://dx.doi.org/10.1038/sj.bjc.6690543}},
doi = {{10.1038/sj.bjc.6690543}},
volume = {{80}},
year = {{1999}},
}